Trial Profile
A Randomized, Open-Label, Parallel-Arm Study Comparing the Effect of Once-weekly Dulaglutide With Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes and Moderate or Severe Chronic Kidney Disease
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 02 Aug 2023
Price :
$35
*
At a glance
- Drugs Dulaglutide (Primary) ; Insulin glargine; Insulin lispro
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms AWARD-7
- Sponsors Eli Lilly and Company
- 26 Jun 2023 Results of a post hoc analyses assessing longitudinal changes of plasma proteins associated with progression to end-stage kidney disease in type 2 diabetes patients with chronic kidney disease treated with Dulaglutide presented at the 83rd Annual Scientific Sessions of the American Diabetes Association
- 25 Sep 2020 Results assessing exploratory analysis assessing changes in urinary C3Mand plasma PRO-C6 in response to treatment with dulaglutide 1.5 mg compared to insulin glargine, presented at the 56th Annual Meeting of the European Association for the Study of Diabetes
- 16 Jun 2020 Results assessing exploratory analysis assessing changes in urinary C3M and plasma PRO-C6 in response to treatment with dulaglutide 1.5 mg compared to insulin glargine in this study, were presented at the 80th Annual Scientific Sessions of the American Diabetes Association.